Specific peptides for the therapeutic targeting of oncogenes

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Tumors rely on specific oncogenic proteins for survival.
• Targeting these proteins is crucial for effective cancer therapy.
• Protein interfaces are often challenging targets for small molecule drugs.

Purpose of the Study:

• To explore the potential of cell-permeable peptides as targeted cancer therapeutics.
• To investigate peptide interference with oncogenic proteins for clinical translation.
• To evaluate the efficacy and safety of novel anti-tumor peptides.

Main Methods:

• Development of stable, cell-permeable peptide inhibitors.
• Testing peptide efficacy against various tumors in vitro and in vivo.
• Assessing peptide toxicity in normal tissues.

Main Results:

• A peptide inhibitor of Heat Shock Protein 90 (Hsp90) demonstrated broad anti-tumor activity.
• A peptide inhibitor targeting the B-cell lymphoma 6 (BCL6) oncoprotein showed efficacy in B-cell lymphomas.
• Both tested peptides exhibited activity without causing toxicity to normal tissues.

Conclusions:

• Cell-permeable peptides represent a promising strategy for targeting oncogenic proteins in cancer.
• These peptides offer a potential for targeted cancer therapy with a favorable safety profile.
• Further clinical translation of peptide-based cancer therapies is warranted.